Literature DB >> 1355728

Treatment of acromegaly with dopamine agonists.

C A Jaffe1, A L Barkan.   

Abstract

This article reviews the current understanding of how dopamine agonists stimulate growth hormone secretion in normal individuals, yet suppress growth hormone secretion in acromegaly patients. Although bromocriptine normalizes growth hormone or somatomedin C hypersecretion in a minority of patients, a significant number of subjects have a clinical response. Side effects of bromocriptine treatment and newer dopamine agonists are discussed. These drugs can be useful medical therapy, either used alone in selected patients or in combination with other therapeutic modalities.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1355728

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  40 in total

Review 1.  Receptor imaging in the diagnosis and treatment of pituitary tumors.

Authors:  D J Kwekkeboom; W W de Herder; E P Krenning
Journal:  J Endocrinol Invest       Date:  1999-01       Impact factor: 4.256

Review 2.  Therapy of diabetes and dyslipidemia in acromegaly.

Authors:  G Tamburrano; C Durante; R Baldelli
Journal:  Pituitary       Date:  2002-01       Impact factor: 4.107

Review 3.  Treatment options in acromegaly. Benefits and costs.

Authors:  L M Weekes; K K Ho; J P Seale
Journal:  Pharmacoeconomics       Date:  1996-11       Impact factor: 4.981

Review 4.  Growth hormone and its disorders.

Authors:  J Ayuk; M C Sheppard
Journal:  Postgrad Med J       Date:  2006-01       Impact factor: 2.401

Review 5.  GH receptor antagonist: mechanism of action and clinical utility.

Authors:  Sowmya K Surya; Ariel L Barkan
Journal:  Rev Endocr Metab Disord       Date:  2005-01       Impact factor: 6.514

6.  Treatment of pituitary tumors: history.

Authors:  Gaya Thanabalasingham; Niki Karavitaki; Simon Cudlip; John A H Wass
Journal:  Endocrine       Date:  2005-10       Impact factor: 3.633

Review 7.  Treatment of acromegaly: future.

Authors:  Ines Donangelo; Shlomo Melmed
Journal:  Endocrine       Date:  2005-10       Impact factor: 3.633

8.  Pituitary gland: Medical therapy for acromegaly: can we predict response?

Authors:  Andrea Giustina; Teresa Porcelli
Journal:  Nat Rev Endocrinol       Date:  2009-08       Impact factor: 43.330

Review 9.  The role of combination medical therapy in the treatment of acromegaly.

Authors:  Dawn Shao Ting Lim; Maria Fleseriu
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

Review 10.  Nanomedicines in the treatment of acromegaly: focus on pegvisomant.

Authors:  Ferdinand Roelfsema; Nienke R Biermasz; Alberto M Pereira; Johannes Romijn
Journal:  Int J Nanomedicine       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.